258 related articles for article (PubMed ID: 11911607)
21. Beginning to manage drug discovery and development knowledge.
Sumner-Smith M
Curr Opin Drug Discov Devel; 2001 May; 4(3):319-24. PubMed ID: 11560065
[TBL] [Abstract][Full Text] [Related]
22. Advances in knowledge management for pharmaceutical research and development.
Torr-Brown S
Curr Opin Drug Discov Devel; 2005 May; 8(3):316-22. PubMed ID: 15892246
[TBL] [Abstract][Full Text] [Related]
23. Transforming the work of early-stage drug discovery through bioprocess informatics.
Holzman TF; Hebert EJ
Drug Discov Today; 2005 Jan; 10(1):61-7. PubMed ID: 15676300
[TBL] [Abstract][Full Text] [Related]
24. The evolution to electronic data interchange: are there benefits at all stages of implementation?
Lummus RR
Hosp Mater Manage Q; 1997 May; 18(4):79-83. PubMed ID: 10168466
[TBL] [Abstract][Full Text] [Related]
25. The impact of FDA guidance on pharmacogenomic data submissions on drug development.
Little S
IDrugs; 2005 Aug; 8(8):648-50. PubMed ID: 16044373
[TBL] [Abstract][Full Text] [Related]
26. Paving the critical path: how can clinical pharmacology help achieve the vision?
Lesko LJ
Clin Pharmacol Ther; 2007 Feb; 81(2):170-7. PubMed ID: 17259944
[TBL] [Abstract][Full Text] [Related]
27. Antibacterial research and development in the 21(st) Century--an industry perspective of the challenges.
Thomson CJ; Power E; Ruebsamen-Waigmann H; Labischinski H
Curr Opin Microbiol; 2004 Oct; 7(5):445-50. PubMed ID: 15451498
[TBL] [Abstract][Full Text] [Related]
28. Development of a functional, internet-accessible department of surgery outcomes database.
Newcomb WL; Lincourt AE; Gersin K; Kercher K; Iannitti D; Kuwada T; Lyons C; Sing RF; Hadzikadic M; Heniford BT; Rucho S
Am Surg; 2008 Jun; 74(6):548-54; discussion 554. PubMed ID: 18556999
[TBL] [Abstract][Full Text] [Related]
29. Implications of pharmacogenomics for drug development.
Kirk RJ; Hung JL; Horner SR; Perez JT
Exp Biol Med (Maywood); 2008 Dec; 233(12):1484-97. PubMed ID: 18849536
[TBL] [Abstract][Full Text] [Related]
30. Pharmaceutical new product development: the increasing role of in-licensing.
Edwards NV
Anesthesiol Clin; 2008 Dec; 26(4):627-36, v. PubMed ID: 19041620
[TBL] [Abstract][Full Text] [Related]
31. The value of drug repositioning in the current pharmaceutical market.
Tobinick EL
Drug News Perspect; 2009 Mar; 22(2):119-25. PubMed ID: 19330170
[TBL] [Abstract][Full Text] [Related]
32. Affinity-based screening techniques for enhancing lead discovery.
Comess KM; Schurdak ME
Curr Opin Drug Discov Devel; 2004 Jul; 7(4):411-6. PubMed ID: 15338950
[TBL] [Abstract][Full Text] [Related]
33. Conducting pharmaceutical R&D in India - Critical components of entry strategies.
Gulati R
IDrugs; 2008 Nov; 11(11):817-22. PubMed ID: 18988126
[TBL] [Abstract][Full Text] [Related]
34. Scientific workflows as productivity tools for drug discovery.
Shon J; Ohkawa H; Hammer J
Curr Opin Drug Discov Devel; 2008 May; 11(3):381-8. PubMed ID: 18428092
[TBL] [Abstract][Full Text] [Related]
35. Advances in solid dosage form manufacturing technology.
Andrews GP
Philos Trans A Math Phys Eng Sci; 2007 Dec; 365(1861):2935-49. PubMed ID: 17855217
[TBL] [Abstract][Full Text] [Related]
36. The promise of pharmacogenetics: assessing the prospects for disease and patient stratification.
Smart A; Martin P
Stud Hist Philos Biol Biomed Sci; 2006 Sep; 37(3):583-601. PubMed ID: 16980196
[TBL] [Abstract][Full Text] [Related]
37. Data is the currency of R&D, and that currency is now generated and traded globally.
Brown FK; Maliski E; Waller C
Curr Opin Drug Discov Devel; 2010 May; 13(3):275-8. PubMed ID: 20464800
[TBL] [Abstract][Full Text] [Related]
38. The interaction between intellectual property and drug regulatory systems: global perspectives.
Madden EA
IDrugs; 2007 Feb; 10(2):116-20. PubMed ID: 17285464
[TBL] [Abstract][Full Text] [Related]
39. [Early achievements of the Danish pharmaceutical industry--2. The minor and almost forgotten pharmaceutical companies].
Grevsen JV; Kirkegaard H; Kruse E; Kruse PR
Theriaca; 2009; (38):7-71. PubMed ID: 20027788
[TBL] [Abstract][Full Text] [Related]
40. Relationship between pharmaceutical company user fees and drug approvals in Canada and Australia: a hypothesis-generating study.
Lexchin J
Ann Pharmacother; 2006 Dec; 40(12):2216-22. PubMed ID: 17132811
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
